Legend Biotech
LEGNLEGN · Stock Price
Historical price data
Overview
Legend Biotech's mission is to discover, develop, and commercialize transformative cell therapies for patients with life-threatening diseases, primarily in oncology. Its core achievement is the successful global launch of CARVYKTI® (cilta-cel), a best-in-class CAR-T therapy for multiple myeloma, which has propelled the company to commercial leadership and validated its technology platform. The company's strategy centers on deepening its commercial footprint, advancing a broad pipeline of next-generation cell therapies, and expanding its manufacturing capabilities, all underpinned by a strategic global collaboration with Janssen (Johnson & Johnson).
Technology Platform
A proprietary, integrated, and technology-agnostic cell therapy platform for developing and manufacturing autologous and allogeneic cellular immunotherapies, including CAR-T, CAR-NK, and TCR-based therapies.
Pipeline
36| Drug | Indication | Stage | Watch |
|---|---|---|---|
| LCAR-B38M CAR-T Cell | Multiple Myeloma | Phase 2 | |
| LCAR-B38M CAR-T cell injection | Refractory or Relapsed Multiple Myeloma | Phase 1/2 | |
| LCAR-AIO T cells | Multiple Sclerosis (MS) | Phase 1 | |
| LCAR-HL30 cells | Hodgkin's Lymphoma | Phase 1 | |
| LCAR-AIO Cells | Acute Lymphocytic Leukemia | Phase 1 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Legend competes directly with Bristol Myers Squibb/2seventy bio's Abecma in multiple myeloma, and with major cell therapy players like Gilead/Kite and Novartis in hematologic cancers. Its push into solid tumors and allogeneic therapies places it in a more fragmented but high-potential competitive field against numerous clinical-stage biotechs.
Company Timeline
Founded in Somerset, United States
Series A: $50.0M
IPO — $487.0M